Asia Pacific Bioprocess Technology Market Forecast to 2028 - Regional Analysis By Type, Modality, and End User

The Asia Pacific bioprocess technology market is expected to grow from US$ 4,608.64 million in 2023 to US$ 11,000.75 million by 2028. It is estimated to grow at a CAGR of 19.0% from 2023 to 2028.

Emergence of Automated Real‐Time Flow Cytometry (ART‐FCM) Drive Asia Pacific Bioprocess Technology Market

Flow cytometry (FCM) and its technological possibilities have greatly advanced in the past decade as an analysis tool for single-cell properties and population distributions of different cell types in bioreactors. Along the way, a few automated Real‐Time Flow Cytometry (ART‐FCM) solutions were developed for monitoring bioreactor processes without operator interference over extended periods with a variable sampling frequency. ART‐FCM enables s long-term measurements without missing any important events in bioprocesses and uncovers temporal phenomena that are likely unknown and should be investigated in greater detail. Also, more frequent measurements can be performed at a user-defined frequency, independent of the availability of personnel. When compared with methods such as omics that are only partially available on a single-cell level, multi-parameter measurements can be easily established without the extended effort of labor and time via ART-FCM. Compared with conventional FCM studies, microfluidic devices great future potential as ART‐FCM on a chip. In this context, parallelization might become more relevant, as samples from different bioreactors or different locations inside a bioreactor setup could be analyzed simultaneously. Many aspects might also be adapted to other experimental setups where fast and reproducible real-time monitoring of fluorescent process parameters is also of interest. In conclusion, ART‐FCM will most probably advance exponentially in the upcoming years.

Asia Pacific Bioprocess Technology Market Overview

The bioprocessing capacity globally has increased at an average of 12% since the past decade, as per the BioPlan Associates Top 1000 Biofacility Index and Biomanufacturers Database report. China is well positioned as a global participant in markets with both small and large-molecule drugs, accounting for second and third position, respectively, worldwide. Also, China is home to several developers of cell and gene therapy due to China's base for contract development and manufacturing organizations (CDMOs), accounting for ~25% of the country's bioproduction capacity. Therefore, China has considerable biomanufacturing capabilities but strict adherence to the global GMP standards that build confidence in the biologics' safety and effectiveness.
Asia Pacific Bioprocess Technology Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Bioprocess Technology Market Segmentation

The Asia Pacific bioprocess technology market is segmented into type, modality, end user, and country.

Based on type, the Asia Pacific bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, consumables & accessories, and others. In 2023, the consumables & accessories segment registered the largest share in the Asia Pacific bioprocess technology market.

Based on modality, the Asia Pacific Bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the Asia Pacific bioprocess technology market.

Based on end-use, the Asia Pacific Bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered the largest share in the Asia Pacific bioprocess technology market.

Based on country, the Asia Pacific Bioprocess technology market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China segment registered a largest share in the Asia Pacific bioprocess technology market.

Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific bioprocess technology market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific bioprocess technology market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific bioprocess technology market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the bioprocess technology market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution